Benefits And Science

Three trials tested PEA for exercise recovery and muscle soreness. One found a biomarker signal, one was clearly null, one was more complicated.

What the glaucoma trials on PEA measured, including the 2011 crossover study and normal-tension data, and how much eye pressure actually changed.

Veterinarians have used palmitoylethanolamide in dogs and cats for years. Here’s what a 2026 randomized trial and the older dermatology research actually show, and why giving your pet a human PEA capsule isn’t the same thing.

A case report on PEA for restless legs syndrome: what it documented, why the mechanism is plausible, and why one case is not evidence of effect.

What the 2018 trial of PEA in autism spectrum disorder actually tested, what the results showed, and what it does not establish for families.

PEA for dry eye disease: the pilot trial in glaucoma-related ocular surface disease, the preclinical data, and how eye drops differ from oral PEA.

What a 2025 randomized trial of PEA for menstrual pain tested, how large the effect was, and what the study does not tell you about dysmenorrhea.

PEA vs boswellia for joint inflammation: what the evidence supports for each, how the two compare fairly, and why some products combine them.

Why PEA and luteolin keep appearing together: what luteolin adds, the post-COVID olfactory and stroke rehabilitation data, and where it does not apply.

What the human trial on PEA for TMJ pain found, what animal research adds, and how the nerve pain evidence applies to dental pain more broadly.

PEA for chemotherapy-induced neuropathy: a promising 2011 pilot, a 2024 phase II trial with a different result, and what cancer patients should know.

What the sciatica evidence for PEA rests on: a post hoc reanalysis, newer delivery research, and how it differs from PEA’s other pain evidence.